相关实验视频
Updated: May 23, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在克罗恩氏病中Upadacitinib的现实有效性和安全性:一项多中心研究
Jalpa Devi1, Anthony Xu2, Molly Stone3
1Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri.
乌帕达西丁 (UPA) 在现实环境中有效诱导克罗恩病 (CD) 患者的临床和内镜缓解. 这种口服的 Janus 激酶 1 抑制剂显示出良好的安全性,即使在先前接受过先进治疗的患者中也是如此.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 是一种慢性炎症性肠病.
- 乌帕达西丁 (UPA) 是一种口服的Janus激酶1抑制剂.
- 关于CD中UPA有效性和安全性的现实数据有限.
研究的目的:
- 评估乌帕达西提尼布 (UPA) 在患有克罗恩病 (CD) 的成年患者的实际有效性和安全性.
- 评估12周和6个月的临床和内镜缓解率.
- 确定与治疗结果相关的因素,并报告不良事件.
主要方法:
- 在美国9个中心对334名成年CD患者进行了回顾性分析,这些患者接受了UPA (45 mg) 诱导疗法.
- 主要终点:临床缓解12周和内镜缓解6个月.
- 二级结局:X光学,组织学结局和不良事件.
主要成果:
- 在12周后52.1%的患者和6个月后55.9%的患者实现了临床缓解.
- 在6个月内观察到42.7%的内镜缓解.
- 在先进疗法未经治疗的患者中,缓解率更高;较长的疾病持续时间和较高的BMI与较低的缓解率相关. 不良事件发生在13.5%,UPA停止在19.1%.
结论:
- 在现实CD患者队列中,upadacitinib在诱导临床和内镜缓解方面表现出有效性.
- 即使在以前接触过多种先进疗法的患者中也观察到有效性.
- 在这个队列中,UPA治疗没有发现新的安全问题.
更多相关视频
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...